- Title
- Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients
- Creator
- Thomas, Dennis; McDonald, Vanessa M.; Gillman, Andrew; Hew, Mark; Hodge, Sandra; James, Alan; Jenkins, Christine; Katelaris, Constance H.; Katsoulotos, Gregory P.; Langton, David; Lee, Joy; Marks, Guy; Stevens, Sean; Peters, Matthew; Radhakrishna, Naghmeh; Reynolds, Paul N.; Rimmer, Janet; Sivakumaran, Pathmanathan; Upham, John W.; Wark, Peter; Yang, Ian A.; Gibson, Peter G.; Harvey, Erin S.; Baraket, Melissa; Bardin, Philip; Bowden, Jeffrey J.; Bowler, Simon; Chien, Jimmy; Chung, Li Ping
- Relation
- Allergy Vol. 79, Issue 2, p. 384-392
- Publisher Link
- http://dx.doi.org/10.1111/all.15867
- Publisher
- Wiley-Blackwell Publishing Ltd.
- Resource Type
- journal article
- Date
- 2023
- Description
- Background: Asthma remission has emerged as a potential treatment goal. This study evaluated the effectiveness of two biologics (mepolizumab/omalizumab) in achieving asthma remission. Methods: This observational study included 453 severe asthma patients (41% male; mean age ± SD 55.7 ± 14.7 years) from two real-world drug registries: the Australian Mepolizumab Registry and the Australian Xolair Registry. The composite outcome clinical remission was defined as zero exacerbations and zero oral corticosteroids during the previous 6 months assessed at 12 months and 5-item Asthma Control Questionnaire (ACQ-5) ≤1 at 12 months. We also assessed clinical remission plus optimization (post-bronchodilator FEV1 ≥80%) or stabilization (post-bronchodilator FEV1 not greater than 5% decline from baseline) of lung function at 12 months. Sensitivity analyses explored various cut-offs of ACQ-5/FEV1 scores. The predictors of clinical remission were identified. Results: 29.3% (73/249) of AMR and 22.8% (37/162) of AXR cohort met the criteria for clinical remission. When lung function criteria were added, the remission rates were reduced to 25.2% and 19.1%, respectively. Sensitivity analyses identified that the remission rate ranged between 18.1% and 34.9% in the AMR cohort and 10.6% and 27.2% in the AXR cohort. Better lung function, lower body mass index, mild disease and absence of comorbidities such as obesity, depression and osteoporosis predicted the odds of achieving clinical remission. Conclusion: Biologic treatment with mepolizumab or omalizumab for severe asthma-induced asthma remission in a subgroup of patients. Remission on treatment may be an achievable treatment target and future studies should consider remission as an outcome measure.
- Subject
- asthma; mepolizumab; omalizumab; remission; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1498905
- Identifier
- uon:54560
- Identifier
- ISSN:0105-4538
- Rights
- X
- Language
- eng
- Reviewed
- Hits: 1613
- Visitors: 1608
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|